Contact Lens Spectrum

References

July 2015

Document #236

(p. 12) Research Review – Studies Examine Risk Factors for Dry Eye Disease
By Eric Papas, PhD, MCOptom, DIPCL, FAAO

    1. Ahn JM, Lee SH, Rim TH, Park RJ, Yang HS, Kim TI, Yoon KC, Seo KY. Prevalence of and risk factors associated with dry eye: The Korea National Health and Nutrition Examination Survey 2010-2011. Am J Ophthalmol. 2014 Dec;158:1205-1214.e7.

    2. Paulsen AJ, Cruickshanks KJ, Fischer ME, Huang GH, Klein BE, Klein R, Dalton DS. Dry eye in the beaver dam offspring study: prevalence, risk factors, and health-related quality of life. Am J Ophthalmol. 2014 Apr;157:799-806.

    3. Tan LL, Morgan P, Cai ZQ, Straughan RA. Prevalence of and risk factors for symptomatic dry eye disease in Singapore. Clin Exp Optom. 2015 Jan;98:45-53.

    4. Liu NN, Liu L, Li J, Sun YZ. Prevalence of and risk factors for dry eye symptom in mainland China: A systematic review and meta-analysis. J Ophthalmol. 2014;2014:748654.

    5. Yang W, Yang Y, Cao J, Man ZH, Yuan J, Xiao X, Xing YQ. Risk Factors for Dry Eye Syndrome: A Retrospective Case-Control Study. Optom Vis Sci. 2015 March 10. [Epub ahead of print].

    6. Vehof J, Kozareva D, Hysi PG, Hammond CJ. Prevalence and risk factors of dry eye disease in a British female cohort. Br J Ophthalmol. 2014 Dec;98:1712-1717.

    7. Karaiskos D, Mavragani CP, Makaroni S, Zinzaras E, Voulgarelis M, Rabavilas A, Moutsopoulos HM. Stress, coping strategies and social support in patients with primary Sjögren’s syndrome prior to disease onset: a retrospective case-control study. Ann Rheum Dis. 2009 Jan;68:40-46.

    8. Bourcier T, Acosta MC, Borderie V, Borrás F, Gallar J, Bury T, Laroche L, Blemonte C. Decreased corneal sensitivity in patients with dry eye. Invest Ophthalmol Vis Sci. 2005 Jul;46:2341-2345.

    9. Wirth M, Nepp J. Corneal sensitivity in dry eye: A longitudinal pilot study. Spektrum der Augenheilkunde. 2014;28(3):93-101.

    10. Li J, Zheng K, Deng Z, Zheng J, Ma H, Sun L, Chen W. Prevalence and risk factors of dry eye disease among a hospital-based population in southeast China. Eye Contact Lens. 2015 Jan;41:44-50.

(p. 14) Prescribing for Presbyopia – Is It the Eye or the Lens?
By Craig W. Norman, FCLSA

    1. Quinn T. Presbyopes and Daily Disposable Lenses. Contact Lens Spectrum. 2015 May;30:15.

    2. Cox S, Nichols J. Daily Disposables for the 21st Century. Contact Lens Spectrum. 2015 Jun;30:22-23, 25-26, 28.

(p. 15) GP Insights – Corneal Desiccation in Today’s GP Lens Wearers
By Javeria Azhar, OD; Edward S. Bennett, OD, MSEd, FAAO; & Carmen F. Castellano, OD, FAAO

    1. Bennett ES. Lens design and troubleshooting. In: Bennett ES, Grohe RM, eds. Rigid Gas-Permeable Contact Lenses. New York, NY: Professional Press; 1986:189-224.

    2. Edrington TB, Barr JT. Peripheral corneal desiccation. Contact Lens Spectrum. 2002 Jan;17:46.

    3. Henry VA, Bennett ES, Forrest JF. Clinical investigation of the Paraperm EW rigid gas-permeable contact lens. Am J Optom Physiol Opt. 1987 May;64:313-320.

    4. Fonn D, Sorbara L. Rigid Gas-permeable lens problem solving. In: Bennett ES, Weissman BA, eds. Clinical Contact Lens Practice. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:341-354.

    5. Ghormley N, Bennett ES, Schnider C. Corneal desiccation – Clinical management. Int Cont Lens Clin. 1990 Jan-Feb;17:5-8.

    6. Bennett ES, Scheid T, Morgan BW. Gas-permeable lens problem solving. In: Bennett ES, Henry VA. Clinical Manual of Contact Lenses. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2014:211-213.

    7. Bennett ES. Corneal desiccation: How to manage the most common GP Problem. Rev Optom. 2005 Sept;(suppl):10.

    8. Van der Worp E, de Brabander J, Swarbrick HA, Nuijts R, Hendrikse F. Corneal desiccation in rigid contact lens wear: 3- and 9-o’clock staining. Optom Vis Sci. 2003 Apr;80:280-290.

    9. Van der Worp E, de Brabander J, Swarbrick HA, Hendrikse F. Evaluation of signs and symptoms in 3- and 9-o’clock staining. Optom Vis Sci. 2009 Mar;86:260-265.

    10. Van der Worp E, de Brabander J, Swarbrick H, Hendrikse F. Eyeblink frequency and type in relation to 3- and 9-o’clock staining and gas permeable contact lens variables. Optom Vis Sci. 2008 Sept;85:E857-E866.

    11. Schnider CM, Terry RL, Holden BA. Effects of lens design on peripheral corneal desiccation. J Am Optom Assoc. 1997 Mar;68:163-170.

    12. Bennett ES. Gas-permeable material selection. In Bennett ES, Henry VA. Clinical Manual of Contact Lenses (4th ed.), Philadelphia, Wolters Kluwer/Williams & Wilkins, 2014:89-111.

    13. Edrington T, Barr JT. We have edge lift. Contact Lens Spectrum. 2002 Oct;17:49.

    14. Musset A, Stone J. Contact Lens Design Tables. London, Butterworths, 1981:1-12.

    15. Bennett ES. The effect of varying axial edge lift on silicone/acrylate lens performance. Contact Lens J 1986;14(4):3-7.

    16. Grohe RM, Caroline PJ. RGP non-wetting syndrome. Contact Lens Spectrum. 1989 Mar;4:32-44.

    17. Azhar J, Bennett ES, Castellano CF. The incidence of corneal desiccation in today’s gas permeable lens wearers. Poster presented at the Global Specialty Lens Symposium, Las Vegas, January 2015.

(p. 18) Dry Eye Dx and Tx – Treating Dry Eye: Is There Hope on the Horizon?
By William Townsend, OD, FAAO

    1. Bron AJ, Tomlinson A, Foulks GN, Pepose JS, Baudouin, Geerling G, Nichols KK, Lemp MA. Rethinking dry eye disease: a perspective on clinical implications. Ocul Surf. 2014 Apr;12(2 Suppl):S1-S31.

    2. Paulsen AJ, Cruickshanks KJ, Fischer ME, Fischer ME, Huang GH, Klein BE, Klein R, Dalton DS. Dry eye in the beaver dam offspring study: prevalence, risk factors, and health-related quality of life. Am J Ophthalmol. 2014 Apr;157:799-806.

    3. http://www.forbes.com/sites/bernardmunos/2015/01/02/the-fda-approvals-of-2014. Accessed 2015.

    4. https://clinicaltrials.gov/ct2/show/study/NCT01804361.

    5. http://www.inchem.org/documents/jecfa/jecmono/v46je05.htm.

    6. http://www.news-medical.net/health/What-are-Growth-Hormones.aspx. Accessed June 2015.

    7. https://clinicaltrials.gov/ct2/show/NCT02101281.

    8. Tanriverdi F, Borlu M, Atmaca H, Koc, CA, Unluhizarci, Utas S, Kelestimur F. Investigation of the skin characteristics in patients with severe GH deficiency and the effects of 6 months of GH replacement therapy: a randomized placebo controlled study. Clin Endocrinol (Oxf). 2006 Nov;65:579-585.

    9. https://www.centerwatch.com/drug-information/fda-approved-drugs/drug/819/restasis-cyclosporine-ophthalmic-emulsion.

    10. Kern TJ. Topical cyclosporine therapy for keratoconjunctivitis sicca in dogs. Cornell Vet. 1989 Jul;79:207-209.

    11. Laibovitz RA, Solch S, Andriano K, O’Connell M, Silverman MH. Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca. Cornea. 1993 Jul;12:315-323.

    12. https://clinicaltrials.gov/ct2/show/study/NCT02013791.

(p. 22) Meibomiam Gland Dysfunction: An Update
By Carolina Kunnen, PhD, & Jason J. Nichols, OD, MPH, PhD, FAAO

    1. Nichols KK, Foulks GN, Bron AJ, Glasgow BJ, Dogru M, Tsubota K, Lemp MA, Sullivan DA. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011 Mar 30;52:1922-1929.

    2. Nelson JD, Shimazaki J, Benitez-del-Castillo JM, Craig JP, McCulley JP, Den S, Foulks GN. The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci. 2011 Mar 30;52:1930-1937.

    3. Korb DR, Henriquez AS. Meibomian gland dysfunction and contact lens intolerance. J Am Optom Assoc. 1980 Mar;51:243-251.

    4. Knop E, Knop N, Millar T, Obata H, Sullivan DA. The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Invest Ophthalmol Vis Sci. 2011 Mar 30;52:1938-1978.

    5. Schaumberg DA, Nichols JJ, Papas EB, Tong L, Uchino M, Nichols KK. The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Invest Ophthalmol Vis Sci. 2011 Mar 30;54:1994-2005.

    6. Arita R, Itoh K, Inoue K, Kuchiba A, Yamaguchi T, Amano S. Contact lens wear is associated with decrease of meibomian glands. Ophthalmology. 2009 Mar;116:379-384.

    7. Arita R, Itoh K, Maeda S, Maeda K, Furuta A, Fukuoka S, Tomidokoro A, Amano S. Proposed diagnostic criteria for obstructive meibomian gland dysfunction. Ophthalmology. 2009 Nov;116:2058-2063 e1.

    8. Arita R, Itoh K, Maeda S, Maeda K, Furuta A, Tomidokoro A, Amano S. Meibomian gland duct distortion in patients with perennial allergic conjunctivitis. Cornea. 2010 Aug;29:858-860.

    9. Arita R, Itoh K, Maeda S, Maeda K, Tomidokoro A, Amano S. Efficacy of diagnostic criteria for the differential diagnosis between obstructive meibomian gland dysfunction and aqueous deficiency dry eye. Jpn J Ophthalmol. 2010 Sep;54:387-391.

    10. Nichols JJ, Berntsen DA, Mitchell GL, Nichols KK. An assessment of grading scales for meibography images. Cornea. 2005 May;24:382-388.

    11. Henriquez AS, Korb DR. Meibomian glands and contact lens wear. Br J Ophthalmol. 1981 Feb;65:108-111.

    12. Ong BL, Larke JR. Meibomian gland dysfunction: some clinical, biochemical and physical observations. Ophthalmic Physiol Opt. 1990 Apr;10;144-148.

    13. Villani E, Ceresara G, Beretta S, Magnani F, Viola F, Ratiglia R. In vivo confocal microscopy of meibomian glands in contact lens wearers. Invest Ophthalmol Vis Sci. 2011 Jul 13;52:5215-5219.

    14. Hom MM, Martinson JR, Knapp LL, Paugh JR. Prevalence of meibomian gland dysfunction. Optom Vis Sci. 1990 Sep;67:710-712.

    15. Marren SE. Contact-Lens Wear, Use of Eye Cosmetics, and Meibomian Gland Dysfunction. Optom Vis Sci. 1994 Jan;71:60-62.

    16. Nichols JJ, Sinnott LT. Tear film, contact lens, and patient factors associated with corneal staining. Invest Ophthalmol Vis Sci. 2011 Feb 28;52:1127-1137.

    17. Tomlinson A, Bron AJ, Korb DR, Amano S, Paugh JR, Pearce EI, Yee R, Yokoi N, Arita R, Dogru M. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci. 2011 Mar 30;52:2006-2049.

    18. Meadows JF, Ramamoorthy P, Nichols JJ, Nichols KK. Development of the 4-3-2-1 meibum expressibility scale. Eye Contact Lens. 2012 Mar;86-92.

    19. Blackie CA, Korb DR, Knop E, Bedi R, Knop N, Holland EJ. Nonobvious obstructive meibomian gland dysfunction. Cornea. 2010 Dec;29:1333-1345.

    20. Norn M. Meibomian orifices and Marx’s line. Studied by triple vital staining. Acta Ophthalmol (Copenh). 1985 Dec;63:698-700.

    21. Korb DR, Blackie CA. Meibomian gland diagnostic expressibility: correlation with dry eye symptoms and gland location. Cornea. 2008 Dec;27:1142-1147.

    22. Blackie CA, Korb DR. Recovery time of an optimally secreting meibomian gland. Cornea. 2009 Apr;28:293-297.

    23. Blackie CA, Korb DR. The diurnal secretory characteristics of individual meibomian glands. Cornea. 2010 Jan;29:34-38.

    24. Ibrahim OM, Matsumoto Y, Dogru M, Adan ES, Wakamatsu TH, Goto T, Negishi K, Tsubota K. The efficacy, sensitivity, and specificity of in vivo laser confocal microscopy in the diagnosis of meibomian gland dysfunction. Ophthalmology. 2010 Apr;117:665-672.

    25. Cuevas M, González-Garcia MJ, Cacstellanos E, Quispaya R, Parra Pde L, Fernández I, Calonge M. Correlations among symptoms, signs, and clinical tests in evaporative-type dry eye disease caused by meibomian gland dysfunction (MGD). Curr Eye Res. 2012 Oct;37:855-863.

    26. Srinivasan S, Menzies K, Sorbara L, Jones L. Infrared imaging of meibomian gland structure using a novel keratograph. Optom Vis Sci. 2012 May;89:788-794.

    27. Foulks GN, Bron AJ. Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocul Surf. 2003 Jul;1:107-126.

    28. Bron AJ, Yokoi N, Gaffney EA, Tiffany JM. A solute gradient in the tear meniscus. I. A hypothesis to explain Marx’s line. Ocul Surf. 2011;9:70-91.

    29. Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. Cornea. 2004 Nov;23:762-770.

    30. Tong L, Chaurasia SS, Mehta JS, Beuerman RW. Screening for meibomian gland disease: its relation to dry eye subtypes and symptoms in a tertiary referral clinic in Singapore. Invest Ophthalmol Vis Sci. 2010 Jul;51:3449-3454.

    31. Golebiowski B, Chim K, So J, Jalbert I. Lid margins: sensitivity, staining, meibomian gland dysfunction, and symptoms. Optom Vis Sci. 2012 Oct;89:1443-1449.

    32. Sullivan BD, Crews LA, Messmer EM, Foulks GN, Nichols KK, Baenninger P, Geerling G, Figueiredo F, Lemp MA. Correlations between commonly used objective signs and symptoms for the diagnosis of dry eye disease: clinical implications. Acta Ophthalmol. 2014 Mar;92:161-166.

    33. Pult H, Nichols JJ. A review of meibography. Optom Vis Sci. 2012 May;89:E760-E769.

    34. Arita R, Itoh K, Inoue K, Amano S. Noncontact infrared meibography to document age-related changes of the meibomian glands in a normal population. Ophthalmology. 2008 May;115:911-915.

    35. Feng Y, Gao Z, Feng K, Qu H, Hong J. Meibomian gland dropout in patients with dry eye disease in china. Curr Eye Res. 2014 Oct;39:965-972.

    36. Obata H. Anatomy and histopathology of human meibomian gland. Cornea. 2002 Oct;21(7 Suppl):S70-S74.

    37. Pflugfelder SC, Tseng SC, Sanabria O, Kell H, Garcia CG, Felix C, Fueur W, Reis BL. Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation. Cornea. 1998 Jan;17:38-56.

    38. Pult H, Riede-Pult B. Comparison of subjective grading and objective assessment in meibography. Cont Lens Anterior Eye. 2013 Feb;36:22-27.

    39. Ban Y, Shimazaki-Den S, Tsubota K, Shimazaki J. Morphological evaluation of meibomian glands using noncontact infrared meibography. Ocul Surf. 2013 Jan;11:47-53.

    40. Arita R, Suehiro J, Haraguchi T, Shirakawa R, Tokoro H, Amano S. Objective image analysis of the meibomian gland area. Br J Ophthal. 2014 Jun;98:746-755.

    41. Koh YW, Celik T, Lee HK, Petznick A, Tong L. Detection of meibomian glands and classification of meibography images. J Biomed Opt. 2012 Aug;17:086008.

    42. Pult H, Riede-Pult BH. Non-contact meibography: keep it simple but effective. Cont Lens Anterior Eye. 2012 Apr;35:77-80.

    43. Pult H, Riede-Pult BH, Nichols JJ. Relation between upper and lower lids’ meibomian gland morphology, tear film, and dry eye. Optom Vis Sci. 2012 Mar;89:E310-E315.

    44. Eom Y, Lee JS, Kang SY, Kim HM, Song JS. Correlation between quantitative measurements of tear film lipid layer thickness and meibomian gland loss in patients with obstructive meibomian gland dysfunction and normal controls. Am J Ophthalmol. 2013 Jun;155:1104-1110.e2.

    45. Murakami D, Blackie CA, Pult H, Korb DR. Meibomian gland function cannot be predicted by meibography in patients symptomatic for dry eye. Invest Ophthalmol Vis Sci. 2014 Apr;55:27.

    46. Pult H, Purslow C, Murphy PJ. The relationship between clinical signs and dry eye symptoms. Eye (Lond). 2011 Apr;25:502-510.

    47. Bron AJ, Tiffany JM. The contribution of meibomian disease to dry eye. Ocul Surf. 2004 Apr;2:149-165.

    48. Sullivan DA, Sullivan BD, Evans JE, Schirra F, Yamagami H, Liu M, Richards SM, Suzuki T, Schaumberg DA, Sullivan RM, Dana MR. Androgen deficiency, Meibomian gland dysfunction, and evaporative dry eye. Ann N Y Acad Sci. 2002 Jun;966:211-222.

    49. Shimazaki J, Sakata M, Tsubota K. Ocular surface changes and discomfort in patients with meibomian gland dysfunction. Arch Ophthalmol. 1995 Oct;113:1266-1270.

    50. Mathers WD. Ocular evaporation in meibomian gland dysfunction and dry eye. Ophthalmology. 1993 Mar;100:347-351.

    51. Yokoi N, Mossa F, Tiffany JM, Bron AJ. Assessment of meibomian gland function in dry eye using meibometry. Arch Ophthalmol. 1999 Jun;117:723-729.

    52. Craig JP, Blades K, Patel S. Tear lipid layer structure and stability following expression of the meibomian glands. Ophthalmic Physiol Opt. 1995 Nov;15:569-574.

    53. Craig JP, Willcox MD, Argüeso P, Maissa C, Stahl U, Tomlinson A, Wang J, Yokoi N, Stapleton F; members of the TFOS International Workshop on Contact Lens Discomfort. The TFOS international workshop on contact lens discomfort: report of the contact lens interactions with the tear film subcommittee. Invest Ophthalmol Vis Sci. 2013 Oct;54:TFOS123-TFOS156.

    54. Johnson ME. The Association Between Symptoms of Discomfort and Signs in Dry Eye. Ocul Surf. 2009 Oct;7:199-211.

(p. 29) Platelet-Rich Plasma in the Treatment of Contact Lens Discomfort
By Edward S. Jarka, OD, MS

    1. Fonn D. Targeting contact lens induced dryness and discomfort: what properties will make lenses more comfortable. Optom Vis Sci. 2007 Apr;84:279-285.

    2. Rumpakis, J. New data on contact lens dropouts: An international perspective. Rev Optom. 2010 Jan 15;147:37-44.

    3. Nichols JJ. Contact lenses 2012. Contact Lens Spectrum. 2013;28:24-26, 28-29, 52.

    4. Nichols KK, Redfern RL, Jacob JT, Nelson JD, Fonn D, Forstot SL, Huang JF, Holden BA, Nichols JJ; members of the TFOS International Workshop on Contact Lens Discomfort. The TFOS International Workshop on Contact Lens Discomfort: Report of the Definition and Classification Subcommittee. Invest Ophthalmol Vis Sci. 2013 Oct;54:TFOS14-TFOS19.

    5. Papas EB, Ciolino JB, Jacobs D, Miller WL, Pult H, Sahin A, Srinivasan S, Tauber J, Wolffsohn JS, Nelson JD; members of the TFOS International Workshop on Contact Lens Discomfort. The TFOS International Workshop on Contact Lens Discomfort: Report of the Management and Therapy Subcommittee. Invest Ophthalmol Vis Sci. 2013 Oct;54:TFOS183-TFOS203.

    6. Greer JP. Wintrobe’s Clinical Hematology. 2008. Philadelphia: Lippincott Williams & Wilkins.

    7. Imanishi J, Kamiyama K, Iguchi I, Kita M, Sotozono C, Kinoshita S. Growth factors: importance in wound healing and maintenance of transparency of the cornea. Prog Retin Eye Res. 2000 Jan;19:113-129.

    8. Everts P. Autologous Platelet-Leukocyte Enriched Gel Basics and Efficacy: A novel method to support soft tissue and bone healing. 2007 D&L Graphics, Kerkrade, The Netherlands.

    9. Ferrari M, Zia S, Valbonesi M, Henriquet F, Venere G, Spagnolo S, Grasso MA, Panzani I. A New Technique for Hemodilution, Preparation of Autologous Platelet-Rich Plasma and Intraoperative Blood Salvage in Cardiac Surgery. Int J Artif Organs. 1987 Jan;10:47-50.

    10. Gamradt, SC, Rodeo, SA, Warren, RF. Platelet Rich Plasma in Rotator Cuff Repair. Techniques in Orthopedics. 2007 Mar;22:26-33.

    11. Everts PA, Knape JT, Weibrich G, Schönberger JP, Hoffmann J, Overdevest EP, Box HA, van Zundert A. Platelet-Rich Plasma and Platelet Gel: A Review. J Extra Corpor Technol. 2006 Jun;38:174-187.

    12. Alio JL, Colecha JR, Pastor S, Rodriguez A, Artola A. Symptomatic dry eye treatment with autologous platelet-rich plasma. Ophthalmic Res. 2007;39(3):124-129.

    13. Panda A, Jain M, Vanathi M, Velpandian T, Khokhar S, Dada T. Topical Autologous Platelet-Rich Plasma Eyedrops for Acute Corneal Chemical Injury. Cornea. 2012 Sep;31:989-993.

    14. Alio JL, Pastor S, Ruiz-Colecha J, Rodriguez A, Artola A. Treatment of ocular surface syndrome after LASIK with autologous platelet-rich plasma. J. Refract. Surg. 2007 Jun;23:617-619.

    15. Jarka ES, Kahrhoff M, Crane JB. Dry eye--is inflammation just the tip of the iceberg? Optometry. 2012 Mar;83:111-113.

    16. Fox RI, Chan R, Michelson JB, Belmont JB, Michelson PE. Beneficial effects of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum. 1984 Apr;27:459-461.

    17. Matsumoto Y, Dogru M, Goto E, Ohashi Y, Kojima T, Ishida R, Tsubota K. Autologous serum applicationin the treatment of neurotrophic keratopathy. Ophthalmology. 2004 Jun;111:1115-1120.

    18. Goto E, Shimmura S, Shimazaki J, Tsubota K. Treatment of superior limbic keratoconjunctivitis by application of autologous serum. Cornea. 2001 Nov;20:807-810.

    19. Tsubota K, Goto E, Shimmura S, Shimazaki J. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology. 1999 Oct;106:1984-1989.

    20. Ogawa Y, Okamoto S, Mori T, Yamada M, Mashima Y, Watanabe R, Kuwana M, Tsubota K, Ikeda Y, Ogachi Y. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplant. 2003 Apr;31:579-583.

    21. Hussain M, Shtein RM, Sugar A, Soong HK, Woodward MA, DeLoss K, Mian SI. Long-term use of autologous serum 50% eye drops for the treatment of dry eye disease. Cornea. 2014 Dec;33:1245-51.

    22. Marx, RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent. 2001;10(4):225-228.

    23. Anitua E. The use of plasma-rich growth factors (PRGF) in oral surgery. Pract Proced Aesthet Dent. 2001 Aug;13:487-493.

    24. Anitua E, Sánchez M, Orive G, Andía I. The potential effects of the preparation rich in growth factors (PRGF) in different medical fields. Biomaterials. 2007 Nov;28:4551-4560.

    25. Alio JL, Arnalich-Montiel F, Rodriguez AE. The Role of “Eye Platelet Rich Plasma” (E-Prp) for Wound Healing in Ophthalmology. Curr Pharm Biotechnol. 2012 Jun;13:1257-1265.

    26. Alio JL, Abad M, Artola A, Rodriguez-Prats JL, Pastor S, Ruiz-Colecha J. Use of autologous platelet-rich plasma in the treatment of dormant corneal ulcers. Ophthalmology. 2007 Jul;114:1286-1293.

    27. Alio JL, Colecha JR, Pastor S, Rodriguez A, Artola A. Symptomatic Dry Eye Treatment with Autologous Platelet-Rich Plasma. Ophthalmic Res. 2007;39(3):124-129.

    28. Alio JL, Pastor S, Ruiz-Colecha J, Rodriquez A, Artola A. Treatment of ocular surface syndrome after LASIK with autologous platelet-rich plasma. J Refract Surg. 2007 Jun;23:617-619.

    29. Robertson DM. The effects of silicone hydrogel lens wear on the corneal epithelium and risk for microbial keratitis. Eye Contact Lens. 2013 Jan;39:67–72.

    30. Ladage PM. What does overnight lens wear do to the corneal epithelium? Is corneal refractive therapy different? Eye Contact Lens. 2004 Oct;30:194-197; discussion 205-206.

    31. Beygmanson JP. Effects of contact lens wear on corneal ultrastructure. Cont Lens Anterior Eye. 2001;24(3):115–120.

    32. Lemp MA, Gold JB. The effects of extended-wear hydrophilic contact lenses on the human corneal epithelium. Am J Ophthalmol. 1986 Mar 15;101:274-277.

    33. Carpenter G, Cohen S. Epidermal growth factor. Annu Rev Biochem. 1979;48:193-216.

    34. Nishida T, Tanaka H, Nakagawa S, Sasabe T, Awata T, Manabe R. Fibronectin synthesis by the rabbit cornea: effects of mouse epidermal growth factor and cyclic AMP analogs. Jpn J Ophthalmol. 1984;28(2):196-202.

    35. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res. 2003 Mar 10;284:31-53.

    36. Roberts AB. The ever-increasing complexity of TGF-β signaling. Cytokine Growth Factor Rev. 2002 Feb;13:3-5.

    37. Hongo M, Itoi M, Yamaguchi N, Imanishi J. Distribution of epidermal growth factor (EGF) receptors in rabbit corneal epithelial cells, keratocytes and endothelial cells and the changes induced by transforming growth factor-β1. Exp Eye Res. 1992 Jan;54:9-16.

    38. Efron N, Jones L, Bron AJ, Knop E, Arita R, Barabino S, McDermott AM, Villani E, Willcox MD, Markoulli M; members of the TFOS International Workshop on Contact Lens Discomfort. The TFOS International Workshop on Contact Lens Discomfort: Report of the Contact Lens Interactions with the Ocular Surface and Adnexa Subcommittee. Invest Ophthalmol Vis Sci. 2013 Oct 18;54:TFOS98-TFOS122.

    39. Efron N, Perez-Gomez I, Morgan PB. Confocal microscopic observations of stromal keratocytes during extended contact lens wear. Clin Exp Optom. 2002 May;85:156-160.

    40. Jalbert I, Stapleton F. Effect of lens wear on corneal stroma: preliminary findings. Aust N Z J Ophthalmol. 1999 Jun-Aug;27:211-213.

    41. Weed KH, MacEwen CJ, Cox A, McGhee CN. Quantitative analysis of corneal microstructure in keratoconus utilising in vivo confocal microscopy. Eye (Lond). 2007 May;21:614-623.

    42. Saghizadeh M, Chwa M, Aoki A, Lin B, Pirouzmanesh A, Brown DJ, Ljubimov AV, Kenney MC. Altered expression of growth factors and cytokines in keratoconus, bullous keratopathy and diabetic human corneas. Exp Eye Res. 2001 Aug;73:179-189.

    43. Jester JV, Huang J, Petroll WM, Cavanagh HD. TGF beta induced myofibroblast differentiation of rabbit keratocytes requires synergistic TGF beta, PDGF and integrin signaling. Exp Eye Res. 2002 Dec;75:645-657.

    44. Wilson SE, Chen L, Mohan RR, Liang Q, Liu J. Expression of HGF, KGF, EGF and receptor messenger RNAs following corneal epithelial wounding. Exp Eye Res. 1999 Apr;68:377-397.

    45. Takikawa M, Nakamura S, Nakamura S, et al. Enhanced Effect of Platelet-Rich Plasma Containing a New Carrier on Hair Growth. Dermatol Surg. 2011 Dec;37:1721-1729.

    46. Avila MY. Restoration of Human Lacrimal Function Following Platelet-Rich Plasma Injection. Cornea. 2014 Jan;33:18-21.

(p. 34) Maintainging Ocular Surface Wellness
By Sruthi Srinivasan, PhD, BS Optom, FAAO

    1. Korb DR, Blackie CA. Meibomian gland diagnostic expressibility: correlation with dry eye symptoms and gland location. Cornea. 2008 Dec;27:1142-1147.

    2. Blackie CA, Solomon JD, Scaffidi RC, Greiner JV, Lemp MA, Korb DR. The relationship between dry eye symptoms and lipid layer thickness. Cornea. 2009 Aug;28:789-794.

    3. Jester JV, Rife L, Nii D, Luttrull JK, Wilson L, Smith RE. In vivo biomicroscopy and photography of meibomian glands in a rabbit model of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 1982 May;22:660-667.

    4. Mathers WD, Shields WJ, Sachdev MS, Petroll WM, Jester JV. Meibomian gland dysfunction in chronic blepharitis. Cornea.1991 Jul;10:277-285.

    5. Mathers WD, Daley T, Verdick R. Video imaging of the meibomian gland. Arch Ophthalmol. 1994 Apr;112:448-449.

    6. Nichols JJ, Berntsen DA, Mitchell GL, Nichols KK. An assessment of grading scales for meibography images. Cornea. 2005 May;24:382-388.

    7. Arita R, Itoh K, Inoue K, Kuchiba A, Yamaguchi T, Amano S. Contact lens wear is associated with decrease of meibomian glands. Ophthalmology. 2009 Mar;116:379-384.

    8. Arita R, Itoh K, Inoue K, Amano S. Noncontact infrared meibography to document age-related changes of the meibomian glands in a normal population. Ophthalmology 2008;115:911-915.

    9. Arita R, Itoh K, Maeda S, Maeda K, Amano S. A newly developed noninvasive and mobile pen-shaped meibography system. Cornea. 2013 Mar;32:242-247.

    10. Srinivasan S, Menzies K, Sorbara L, Jones L. Infrared imaging of meibomian gland structure using a novel keratograph. Optom Vis Sci. 2012 May;89:788-794.

    11. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop. Ocul Surf. 2007 Apr;5:75-92.

    12. Farris RL, Gilbard JP, Stuchell RN, Mandel ID. Diagnostic tests in keratoconjunctivitis sicca. Clao J. 1983 Jan-Mar;9:23-28.

    13. Lemp MA. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. Clao J. 1995 Oct;21:221-232.

    14. Gilbard JP, Rossi SR, Gray KL. A new rabbit model for keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci. 1987 Feb;28:225-228.

    15. Tomlinson A, Khanal S, Ramaesh K, Diaper C, McFadyen A. Tear film osmolarity: determination of a referent for dry eye diagnosis. Invest Ophthalmol Vis Sci. 2006 Oct;47:4309-4315.

    16. Sullivan B. Clinical resorts of a first generation lab-on-chip nanolitre tear film osmometer. Ocul Surf. 2005;3:s31.

    17. Zhao Z, Fu H, Skotnitsky CC, Sankaridurg PR, Wilcox MD. IgE antibody on worn highly oxygen-permeable silicone hydrogel contact lenses from patients with contact lens induced papillary conjunctivitis (CLPC). Eye Contact Lens. 2008 Mar;34:117-121.

    18. Dalton K, Jones L. The performance of a novel nanolitre osmometer to investigate diurnal tear film osmolality. Optom Vis Sci.2005;82:E-abstract 055070.

    19. Korb DR, Blackie CA. Debridement-scaling: a new procedure that increases Meibomian gland function and reduces dry eye symptoms. Cornea. 2013 Dec;32:1554-1557.

    20. Mori A, Shimazaki J, Shimmura S, Fujishima H, Oguchi Y, Tsubota K. Disposable eyelid-warming device for the treatment of meibomian gland dysfunction. Jpn J Ophthalmol. 2003 Nov-Dec;47:578-586.

    21. Ishida R, Matsumoto Y, Onguchi T, Kaido M, Iwamuro K, Kobayashi J, Takano Y, Shimazaki J, Goto E, Dogru M, Tsubota K. Tear film with “Orgahexa EyeMasks” in patients with meibomian gland dysfunction. Optom Vis Sci. 2008 Aug;85:684-691.

    22. Matsumoto Y, Dogru M, Goto E, Ishida R, Kojima T, Onguchi T, Yagi Y, Shimazaki J, Tsubota K. Efficacy of a new warm moist air device on tear functions of patients with simple meibomian gland dysfunction. Cornea. 2006 Jul;25:644-650.

    23. Friedland BR, Fleming CP, Blackie CA, Korb DR. A novel thermodynamic treatment for meibomian gland dysfunction. Curr Eye Res. 2011 Feb;36:79-87.

    24. Korb DR, Blackie CA. Restoration of meibomian gland functionality with novel thermodynamic treatment device-a case report. Cornea. 2010 Aug;29:930-933.

(p. 44) Contact Lens Practice Pearls – Gregory J. Nixon, OD, FAAO
By Gregory J. Nixon, OD, FAAO

    1. Nichols KK, Foulks GN, Bron AJ, Glasgow BJ, Dogru M, Tsubota K, Lemp MA, Sullivan DA. The international workshop on meibomian gland dysfunction: Executive Summary. Invest Ophthalmol Vis Sci. 2011 Mar 30;52:1922-1929.

    2. Geerling G, Tauber J, Baudouin C, Goto E, Matsumoto Y, O’Brien T, Rolando M, Tsubota K, Nichols KK. The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on Management and Treatment of Meibomian Gland Dysfunction. Invest Ophthalmol Vis Sci. 2011 Mar 30;52:2050-2064.

    3. Lacroix Z, Léger S, Bitton E. Ex vivo heat retention of different eyelid warming masks. Cont Lens Anterior Eye. 2015 Jun;38:152-156.

(p. 49) Treatment Plan – Treat and Manage Sjögren’s
By William L. Miller, OD, MS, PhD, FAAO

    1. Vitali C, Moutsopoulos HM, Bombardieri S. The European Community Study Group on diagnostic criteria for Sjögren’s syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjögren’s syndrome. Ann Rheum Dis. 1994 Oct;53:637-647.

    2. Shiboski SC, Shiboski CH, Criswell L, Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S Lanfranchi H, Schiødt M, Umehara H, Vivino F, Zhao Y, Dong Y, Greenspan D, Heidenreich AM, Helin P, Kirkham B, Kitagawa K, Larkin G, Li M, Lietman T, Lindegaard J, McNamara N. Sack K, Shirlaw P, Sugai S, Vollenweider C, Whitcher J, Wu A, Zhang S, Zhang W, Greenspan J, Daniels T; Sjögren’s International Collaborative Clinical Alliance (SICCA) Research Groups. American College of Rheumatology classification criteria for Sjögren’s syndrome: a data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken). 2012 Apr;64:475-487.

    3. Petznick A, Tong L, Chung R, Wang JC, Koh M, Salleh R, Waduthantri S. Autologous plasma eyedrops prepared in a closed system: a treatment for dry eye. Eye (Lond). 2013 Sep;27:1102.

    4. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren Syndrome. Ophthalmology. 1999 Apr;106:811-816.

    5. Hong S, Kim T, Chung SH, Kim EK, Seo KY. Recurrence after topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren’s syndrome. J Ocul Pharmacol Ther. 2007 Feb;23:78-82.

    6. Sainz De La Maza Serra M, Simon Castellvi C, Kabbani O. [Nonpreserved topical steroids and lacrimal punctal occlusion for severe keratoconjunctivitis sicca]. Arch Soc Esp Oftalmol. 2000 Nov;75:751-756.

    7. Ramos-Casals M, Tzioufas AG, Stone JH, Sisó A, Bosch X. Treatment of primary Sjögren syndrome: a systematic review. JAMA. 2010 Jul 28;304:452-460.